MedTrace Logo

Hydrochloorthiazide and Hypernatriaemie

NCT01974739 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-06-23

No results posted yet for this study

Summary

Acquired hypernatremia appears to be associated with mortallity in ICU. To reduce hypernatremia and shorten the time of hypernatremia, we investigate the effect of hydrochloorthiazide compared to a placebo

Conditions

  • Hypernatraemia

Interventions

DRUG

Hydrochloorthiazide

DRUG

placebo

Sponsors & Collaborators

  • Frisius Medisch Centrum

    lead OTHER

Principal Investigators

  • Christiaan Boerma, MD · Frisius Medisch Centrum

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01974739 on ClinicalTrials.gov